Editorial: Model organisms in respiratory pharmacology 2023
- PMID: 39872054
- PMCID: PMC11770033
- DOI: 10.3389/fphar.2024.1540222
Editorial: Model organisms in respiratory pharmacology 2023
Keywords: animal model; cell culture; computational modeling; lung; pharmacology; respiratory.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
- Editorial on the Research Topic Model organisms in respiratory pharmacology 2023
References
-
- Heijerman H. G. M., McKone E. F., Downey D. G., Van Braeckel E., Rowe S. M., Tullis E., et al. (2019). Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 394 (10212), 1940–1948. 10.1016/S0140-6736(19)32597-8 - DOI - PMC - PubMed
-
- Ikeda K., Aoyagi J., Hanashiro S., Sawada M., Kyuzen M., Morioka H., et al. (2018). Preventive treatment with lomerizine increases cerebral blood flows during the interictal phase of migraine. J. stroke Cerebrovasc. Dis. official J. Natl. Stroke Assoc. 27 (4), 998–1002. 10.1016/j.jstrokecerebrovasdis.2017.11.004 - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
